Arvinas Inc
Arvinas develops therapeutic medicines to treat disease-causing proteins.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arvinas Inc's stock, expecting it to rise significantly in value.
Financial Health
Arvinas Inc is performing well with strong revenue and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ARVN
Next-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially move the share price; outcomes are binary and timings uncertain, so expect volatility.
Platform Potential
Targeted protein degradation could broaden treatable diseases and create new medicines, though the science is still early and success is not assured.
Partner Collaborations
Industry partnerships can provide funding and development expertise, helping de‑risk programmes, but commercialisation and market uptake remain to be proven.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
